What is Lifesci Capital’s Estimate for TNYA FY2025 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities research analysts at Lifesci Capital increased their FY2025 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a research note issued on Monday, November 10th. Lifesci Capital analyst C. Jubinville now anticipates that the company will post earnings per share of ($0.74) for the year, up from their previous estimate of ($0.81). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share.

Several other analysts have also recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a research note on Tuesday, September 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Tenaya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Tenaya Therapeutics in a report on Monday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.25.

Tenaya Therapeutics Price Performance

NASDAQ:TNYA opened at $1.42 on Wednesday. The firm has a market cap of $231.43 million, a price-to-earnings ratio of -1.82 and a beta of 3.13. The firm’s fifty day moving average price is $1.54 and its 200 day moving average price is $0.99. Tenaya Therapeutics has a 1-year low of $0.36 and a 1-year high of $4.01.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03.

Institutional Trading of Tenaya Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Raiffeisen Bank International AG acquired a new position in Tenaya Therapeutics during the third quarter worth about $553,000. Persistent Asset Partners Ltd purchased a new stake in shares of Tenaya Therapeutics during the 3rd quarter worth approximately $117,000. GSA Capital Partners LLP purchased a new stake in shares of Tenaya Therapeutics during the 3rd quarter worth approximately $748,000. Vanguard Group Inc. grew its holdings in shares of Tenaya Therapeutics by 6.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,064,857 shares of the company’s stock worth $8,205,000 after acquiring an additional 309,530 shares during the period. Finally, Mirador Capital Partners LP increased its stake in Tenaya Therapeutics by 38.2% in the 3rd quarter. Mirador Capital Partners LP now owns 23,500 shares of the company’s stock valued at $38,000 after purchasing an additional 6,500 shares in the last quarter. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.